Cosmo Pharmaceuticals Appoints New Chief Financial Officer
Cosmo Pharmaceuticals has appointed Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Sigalova, who previously served as Vice President of Commercial Finance at Moderna, brings extensive experience in managing multibillion-dollar revenue streams and developing financial infrastructure. She succeeds Niall Donnelly, who will transition to a new role as EVP - Corporate Governance & Chief Sustainability Officer.
In her new position, Donnelly will focus on strengthening Cosmo's corporate governance framework and advancing ESG initiatives, including carbon footprint reduction. He will remain an executive member of the Board of Directors. CEO Giovanni Di Napoli expressed confidence that Sigalova's expertise will guide Cosmo's financial strategy and support its global expansion, while Donnelly's new role will reinforce the company's commitment to responsible growth and long-term value.
Cosmo Pharmaceuticals ha nominato Svetlana Sigalova come nuovo Direttore Finanziario, con effetto dall'11 novembre 2024. Sigalova, che in precedenza ha ricoperto il ruolo di Vicepresidente della Finanza Commerciale presso Moderna, porta con sé una vasta esperienza nella gestione di flussi di entrate da miliardi di dollari e nello sviluppo dell'infrastruttura finanziaria. Succede a Niall Donnelly, che passerà a un nuovo ruolo di EVP - Governance Aziendale e Direttore della Sostenibilità.
Nella sua nuova posizione, Donnelly si concentrerà sul rafforzamento del framework di governance aziendale di Cosmo e sulla promozione delle iniziative ESG, inclusa la riduzione dell'impronta di carbonio. Rimarrà membro esecutivo del Consiglio di Amministrazione. Il CEO Giovanni Di Napoli ha espresso fiducia sul fatto che l'esperienza di Sigalova guiderà la strategia finanziaria di Cosmo e supporterà la sua espansione globale, mentre il nuovo ruolo di Donnelly rafforzerà l'impegno dell'azienda verso una crescita responsabile e un valore a lungo termine.
Cosmo Pharmaceuticals ha nombrado a Svetlana Sigalova como su nueva Directora Financiera, con efecto a partir del 11 de noviembre de 2024. Sigalova, quien anteriormente se desempeñó como Vicepresidenta de Finanzas Comerciales en Moderna, aporta una amplia experiencia en la gestión de flujos de ingresos multimillonarios y en el desarrollo de la infraestructura financiera. Sucede a Niall Donnelly, quien pasará a un nuevo cargo como EVP - Gobernanza Corporativa y Director de Sostenibilidad.
En su nueva posición, Donnelly se enfocará en fortalecer el marco de gobernanza corporativa de Cosmo y en avanzar en las iniciativas ESG, incluida la reducción de la huella de carbono. Permanecerá como miembro ejecutivo de la Junta Directiva. El CEO Giovanni Di Napoli expresó confianza en que la experiencia de Sigalova guiará la estrategia financiera de Cosmo y apoyará su expansión global, mientras que el nuevo rol de Donnelly reforzará el compromiso de la empresa con un crecimiento responsable y un valor a largo plazo.
코스모 제약은 스베틀라나 시갈로바를 새로운 최고재무책임자(CFO)로 임명했습니다. 임기는 2024년 11월 11일부터 시작됩니다. 시갈로바는 이전에 모더나에서 상업 재무 부사장이었으며, 수십억 달러 규모의 수익원을 관리하고 재무 인프라를 구축하는 데 풍부한 경험을 가지고 있습니다. 그녀는 니얼 도넬리를 이어받으며, 도넬리는 새로운 역할인 EVP - 기업 거버넌스 및 최고 지속 가능성 책임자로 전환됩니다.
새로운 직책에서 도넬리는 코스모의 기업 거버넌스 체계를 강화하고 탄소 발자국 감소를 포함한 ESG 이니셔티브를 추진하는 데 집중할 것입니다. 그는 이사회에서 임원으로 남을 것입니다. CEO 지오바니 디 나폴리는 시갈로바의 전문성이 코스모의 재무 전략을 이끌고 글로벌 확장을 지원할 것이라는 확신을 나타내었고, 도넬리의 새로운 역할은 회사의 책임 있는 성장과 지속 가능한 가치를 강화할 것이라고 덧붙였습니다.
Cosmo Pharmaceuticals a nommé Svetlana Sigalova au poste de nouvelle Directrice Financière, avec effet au 11 novembre 2024. Sigalova, qui a précédemment occupé le poste de Vice-présidente des Finances Commerciales chez Moderna, apporte une vaste expérience dans la gestion de flux de revenus de plusieurs milliards de dollars et dans le développement de l'infrastructure financière. Elle succède à Niall Donnelly, qui fera la transition vers un nouveau rôle de EVP - Gouvernance d'Entreprise et Directeur de la Durabilité.
Dans son nouveau poste, Donnelly se concentrera sur le renforcement du cadre de gouvernance d'entreprise de Cosmo et sur la promotion des initiatives ESG, notamment la réduction de l'empreinte carbone. Il restera membre exécutif du Conseil d'Administration. Le CEO Giovanni Di Napoli a exprimé sa confiance dans le fait que l'expertise de Sigalova guidera la stratégie financière de Cosmo et soutiendra son expansion mondiale, tandis que le nouveau rôle de Donnelly renforcera l'engagement de l'entreprise envers une croissance responsable et une valeur à long terme.
Cosmo Pharmaceuticals hat Svetlana Sigalova als neue Finanzvorständin (CFO) ernannt, die am 11. November 2024 ihr Amt antreten wird. Sigalova, die zuvor als Vizepräsidentin für kommerzielle Finanzen bei Moderna tätig war, bringt umfassende Erfahrungen in der Verwaltung von milliardenschweren Einnahmequellen und im Aufbau finanzieller Infrastrukturen mit. Sie tritt die Nachfolge von Niall Donnelly an, der in eine neue Rolle als EVP - Unternehmensführung und Chief Sustainability Officer wechselt.
In ihrer neuen Position wird Donnelly sich darauf konzentrieren, das Corporate-Governance-Rahmenwerk von Cosmo zu stärken und ESG-Initiativen voranzutreiben, einschließlich der Reduzierung des CO2-Fußabdrucks. Er wird weiterhin ein Exekutivmitglied des Vorstands bleiben. CEO Giovanni Di Napoli äußerte Vertrauen, dass Sigalovas Expertise die Finanzstrategie von Cosmo leiten und die globale Expansion unterstützen wird, während Donnellys neue Rolle das Engagement des Unternehmens für verantwortungsvolles Wachstum und langfristigen Wert verstärken wird.
- Appointment of experienced CFO with background in managing multibillion-dollar revenue streams
- Former CFO transitioning to focus on strengthening corporate governance and ESG initiatives
- Strategic move aligned with global expansion plans
- None.
Ad hoc announcement pursuant to Art. 53 LR
Dublin, Ireland--(Newsfile Corp. - October 11, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is delighted to announce the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016.
Svetlana Sigalova brings a wealth of expertise from her time at Moderna, where she served as Vice President of Commercial Finance and led the financial operations for over
Niall will transition to a strategic new role as EVP – Corporate Governance & Chief Sustainability Officer, where he will report to CEO and play a key part in strengthening Cosmo’s corporate governance framework and driving the Company’s mission to advance environmental, social, and governance (ESG) initiatives. With a focus on achieving carbon footprint reduction and sustainable business practices, Niall’s leadership will ensure Cosmo continues to build a strong and responsible organization with a robust governance structure that aligns with the Company’s long-term growth and value creation. He will also remain an executive member of the Board of Directors of Cosmo.
Giovanni Di Napoli, CEO of Cosmo, commented: “Svetlana’s appointment marks a pivotal step in Cosmo’s global expansion strategy. With her extensive experience in fast-growing, global organizations, she will be an invaluable asset in guiding our financial strategy, driving performance, and supporting our mission to enhance our presence in international markets. We are excited to have her expertise as we take Cosmo to the next level.”
Giovanni added: “At the same time, we want to extend our heartfelt gratitude to Niall for his outstanding service as CFO over the past eight years. Niall has been instrumental in shaping Cosmo’s financial foundation, and we are thrilled that he will continue to bring his vast experience and strategic insight to our corporate governance and ESG efforts. His leadership in establishing strong governance frameworks and driving sustainability initiatives will be key in reinforcing the commitment of our Company to responsible growth and long-term value.”
Svetlana Sigalova stated: “I am truly honored to join Cosmo’s dynamic team and excited to work alongside the Management Team and employees to support the company’s ambitious growth plans. It is a privilege to contribute to such an innovative organization with solid revenue drivers and promising R&D projects. I look forward to leveraging my experience to help drive Cosmo’s financial excellence and global expansion.”
About Cosmo
Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. The current growth drivers, including the state-of-the-art GI Genius™ intelligent endoscopy system that enhances polyp detection rates during colonoscopy and the prescription drug Winlevi® to treat acne are generating substantial revenue streams. The Company’s proprietary MMX® technology enables targeted delivery of active ingredients in the colon and is a cornerstone of its product development. Cosmo also has a robust clinical development pipeline, which includes Breezula® for the treatment of androgenetic alopecia. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company currently has approximately 300 employees, all dedicated to making a significant impact in the field of healthcare. For more information, please visit www.cosmopharma.com.
Upcoming Calendar of Events
UBS Global Healthcare Conference, California November 11-14, 2024
Jefferies London Healthcare Conference, London November 19-21, 2024
For further information, please contact
Hazel Winchester
Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
hwinchester@cosmopharma.com
Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.
Attachments
241011_Cosmo Pharma_Media Release_New CFO_EN
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226361
FAQ
Who is the new CFO of Cosmo Pharmaceuticals (CMOPF)?
What is Svetlana Sigalova's background before joining Cosmo Pharmaceuticals (CMOPF)?
What new role will former CFO Niall Donnelly take at Cosmo Pharmaceuticals (CMOPF)?
When will Svetlana Sigalova start as CFO of Cosmo Pharmaceuticals (CMOPF)?
